+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of a Recombinant Human Growth Hormone Preparation on the Urinary 15Nitrogen Balance in Growth-Hormone-Deficient Children

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In 10 patients with idiopathic growth hormone (GH) deficiency (9 boys and 1 girl, aged 7.5–14.5 years, mean 12.1 ± 2.2 years), urinary <sup>15</sup>N-balance studies were performed before and on recombinant hGH (2 × 3 IU/m<sup>2</sup> of body surface area subcutaneously on consecutive days). Before and on the 2nd day of recombinant hGH, 99% <sup>15</sup>N-labeled ammonium chloride (0.05 g/kg, divided in 3 doses per day, corresponding to 389 ± 30 mg/m<sup>2</sup> of <sup>15</sup>N) was administered and 24 h urine was collected. In urine, total nitrogen and the percentage of <sup>15</sup>N were measured. From the ingested and excreted quantity, a urinary <sup>15</sup>N balance was calculated. Mean <sup>15</sup>N percentage from total N was 3.3 ± 0.5. In 9 patients, basal <sup>15</sup>N balance was +79 ± 15 mg/m<sup>2</sup> or +2.9 ± 0.4 mg/kg. On recombinant hGH, it was +166 ± 16 mg/m<sup>2</sup> or +6.1 ± 0.6 mg/kg (p < 0.001). The recombinant hGH-induced positive <sup>15</sup>N balance change was +87 ± 17 mg/m<sup>2</sup> or +3.2 ± 0.6 mg/kg. 1 patient with a higher basal <sup>15</sup>N balance (+196 mg/m<sup>2</sup>, +7.1 mg/kg) had no positive <sup>15</sup>N balance change due to latent hypothalamic hypothyroidism. In previous similar studies with pituitary hGH, the change of <sup>15</sup>N balance was +80 ± 27 mg/m<sup>2</sup> or +2.8 ± 1.1 mg/kg. It is concluded that the acute nitrogen-retaining effect of recombinant hGH is at least equal to that of pituitary hGH.

          Related collections

          Author and article information

          Hormone Research in Paediatrics
          S. Karger AG
          28 November 2008
          : 29
          : 4
          : 140-142
          Departments of Pediatrics, Universities of Zürich, Switzerland, and Vienna, Austria; Eli Lilly Co., Vienna, Austria
          180990 Horm Res 1988;29:140–142
          © 1988 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Original Paper


          Comment on this article